Key Takeaway: Ardelyx reported a strong financial performance for Q2 2026, with total product revenue reaching $118.1 million, marking a 31% increase compared to the previous year. The revenue from IBSRELA grew by 33% to $86.2 million, while XPHOZAH also saw a 27% increase to $31.9 million. The company maintains a robust cash position of $281.8 million.
Market Sentiment Analysis
POSITIVE FACTORS
Total product revenue increased by 31% year-over-year.
IBSRELA revenue grew by 33% year-over-year.
Strong financial position with $281.8 million in cash.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
6.3%
average across 4 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
AZD1722
Phase 1 · Healthy Volunteer
Full Press Release Details
Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents
Frequently Asked Questions
What was Ardelyx's total product revenue for Q2 2026?
Ardelyx's total product revenue for Q2 2026 was $118.1 million.
How much did IBSRELA revenue grow in Q2 2026?
IBSRELA revenue grew by 33% year-over-year to $86.2 million.
What is Ardelyx's cash position as of Q2 2026?
Ardelyx has a strong cash position of $281.8 million.
What was the revenue growth for XPHOZAH in Q2 2026?
XPHOZAH revenue grew by 27% year-over-year to $31.9 million.